PEPT - ETF AI Analysis
Top Page
REX Peptide ETF (PEPT)
PEPT, the REX Peptide ETF, has a solid but not top-tier overall rating, largely supported by strong core holdings like Eli Lilly, Novo Nordisk, and Sanofi, which bring robust financial performance, attractive dividends or valuations, and positive long-term growth stories. However, weaker names such as Ascendis Pharma and Rhythm Pharmaceuticals, with ongoing losses and less attractive valuations, weigh on the fund’s quality. The main risk factor is its heavy concentration in a specialized biotech/pharma niche, where several holdings face profitability and valuation challenges, making the ETF more sensitive to sector-specific setbacks.
PEPT vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.81M
- Region
- Global
- Expense Ratio
- 0.65%
- Beta
- N/A
- Issuer
- REX Shares
- Inception Date
- Oct 14, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- VettaFi Peptide Index - USD - Benchmark TR Net
PEPT Summary
REX Peptide ETF (PEPT) is a health care fund that follows the VettaFi Peptide Index, focusing on companies working with peptide-based medicines and related technologies. It mainly holds drugmakers and biotech firms from the U.S. and Europe, including well-known names like Eli Lilly and Novo Nordisk. Investors might consider PEPT if they want targeted exposure to innovative treatments, especially in areas like diabetes, obesity, and other conditions where peptide drugs are growing fast. However, this ETF is concentrated in a niche part of the health care sector, so its price can be more volatile and may go up and down sharply with biotech news and market sentiment.
How much will it cost me?
This ETF has an expense ratio of 0.65%, which means you’ll pay about $6.50 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because this is a more specialized, sector-focused fund that targets peptide-related health care companies.
What would affect this ETF?
This ETF could benefit if demand for innovative peptide-based drugs keeps growing globally, especially for major holdings like Eli Lilly and Novo Nordisk that are developing treatments for chronic conditions such as diabetes and obesity. On the downside, it is heavily concentrated in health care and biotech, so setbacks in drug trials, tighter regulations on pricing or approvals, or changes in interest rates that hurt high-growth companies could weigh on performance.
PEPT Top 10 Holdings
This peptide-focused ETF leans heavily on a handful of health care names, with Eli Lilly acting as the main engine, steadily climbing and giving the fund a solid blue-chip anchor. Novo Nordisk and Insulet, however, have been losing steam, dragging on recent returns despite their strong franchises. Mid-cap players like Ascendis Pharma and Rhythm Pharmaceuticals are also lagging, adding some bumpiness. On the brighter side, Protagonist Therapeutics and Switzerland’s Bachem are rising, showing how this globally diversified, biotech-heavy portfolio mixes established giants with high-octane innovators in peptide drugs.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 13.16% | $170.13K | $1.21T | 55.12% | 72Outperform |
 ASND | Ascendis Pharma | 10.78% | $139.25K | $15.34B | 20.97% | 46Neutral |
 NVO | Novo Nordisk | 10.22% | $132.06K | $171.22B | -26.89% | 73Outperform |
 PODD | Insulet | 8.42% | $108.81K | $10.39B | -54.01% | 70Outperform |
 PTGX | Protagonist Therapeutics | 7.06% | $91.21K | $9.13B | 87.53% | 68Neutral |
 FR:SAN | Sanofi | 5.35% | $69.11K | EUR 90.14B | -14.73% | 75Outperform |
 RYTM | Rhythm Pharmaceuticals | 4.85% | $62.72K | $6.35B | -17.36% | 59Neutral |
 DAR | Darling Ingredients | 4.49% | $58.07K | $8.78B | 61.55% | 69Neutral |
 CH:BANB | Bachem Holding AG | 3.90% | $50.46K | CHF 6.25B | 42.48% | 64Neutral |
 VKTX | Viking Therapeutics | 3.51% | $45.39K | $3.17B | -30.73% | 53Neutral |
PEPT Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PEPT, the sentiment is Positive. The current price of 26.11 is compared to the 20-day moving average (MA) of , compared to the 50-day MA of , and compared to the 200-day MA of , indicating a neutral trend. The MACD of indicates Neutral momentum. The RSI at is Neutral, neither overbought nor oversold. The STOCH value of is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PEPT.
PEPT Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| PEPT | $26.11 | $27.00(3.42% Upside) | $1.81M | 0.65% | 60Neutral |
 OZEM | $29.50 | $46.47(57.50% Upside) | $54.07M | 0.59% | 55Neutral |
 HRTS | $37.61 | $44.93(19.46% Upside) | $55.46M | 0.75% | 67Neutral |
 FMED | $32.52 | $43.53(33.84% Upside) | $51.68M | 0.50% | 59Neutral |
 PSIL | $21.02 | $53.29(153.53% Upside) | $44.67M | 1.00% | 45Neutral |
 MEDI | $33.89 | $44.68(31.83% Upside) | $43.74M | 0.80% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PEPT | REX Peptide ETF | 26.11 | 1.05 | 4.20% | |
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 29.50 | 2.19 | 8.01% | |
| HRTS | Tema Cardiovascular and Metabolic ETF | 37.61 | 5.73 | 17.96% | |
| FMED | Fidelity Disruptive Medicine ETF | 32.52 | 6.17 | 23.39% | |
| PSIL | AdvisorShares Psychedelics ETF | 21.02 | 2.75 | 15.06% | |
| MEDI | Harbor Health Care ETF | 33.89 | 4.09 | 13.74% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.